Feb 21, 2012

MOUNTAIN VIEW, Calif. - Feb. 21, 2012 - Complete Genomics Inc. (NASDAQ: GNOM) today announced that the company will be included in MIT's Technology Review TR50, an annual list of the 50 most innovative technology companies in the world. It is the third-consecutive year that Complete Genomics has been named to the list.

Companies are nominated by Technology Review that have demonstrated original and valuable technology, have brought that technology to market at a significant scale, and have influenced competitors during the past year. The TR50 list includes companies in the energy, computing and Internet, biomedicine, and materials industries that represent commercial innovations most likely to change lives around the world.

"The new sequencing projects that Complete Genomics has undertaken, enabled by its advanced sequencing technology and computation platform, will make important contributions to understanding diseases such as cancer," said Jason Pontin, editor in chief and publisher of Technology Review.

For researchers and healthcare organizations making strides toward genomic medicine, Complete Genomics provides whole human genome sequencing as a service using its proprietary sequencing platform. In 2011, the company sequenced and delivered more than 3,000 human genomes to its customers.

In August, Complete Genomics announced a project to sequence more than 1,000 additional genomes for the National Cancer Institute's (NCI's) pediatric cancer study. The project is part of an NCI initiative that seeks to use genomics technologies to identify valid therapeutic targets in childhood cancers so new, more effective treatments can be developed.

Complete Genomics also announced in August that it would be partnering with Inova Health System to sequence 1,500 genomes from 500 babies and their parents in an effort to identify prognostic, diagnostic and therapeutic targets for pre-term delivery and potentially other associated defects.

And in October, the company announced a collaboration with Scripps Health, under which Complete Genomics will sequence, at its own cost, the whole human genomes of 1,000 participants in the Wellderly Study. The Wellderly Study aims to unlock the genetic secrets of lifelong health by sequencing the genomes of healthy people age 80 and above.

"Our customers are doing great work discovering the genomic causes of disease and taking the first steps toward personalized medicine," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "We are honored, for the third year in a row, to be included in the TR50 alongside so many other innovative companies."

About Technology Review, Inc.

Technology Review is an independent media company owned by the Massachusetts Institute of Technology. More than three million people around the globe read our publications, in five languages and on a variety of digital and print platforms. We publish Technology Review magazine, the world's oldest technology magazine (established 1899); daily news, analysis, opinion, and video on www.technologyreview.com and several mobile apps; Business Impact, which explains how new technologies are transforming companies, disrupting markets, or creating entirely new industries; and live events including the annual Emtech MIT conference. Technology Review also owns the MIT Enterprise Forum, a community and events organization that fosters technology entrepreneurship with 28 chapters worldwide.

About Complete Genomics

Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics' proprietary human genome sequencing technology with advanced informatics and data management software. Additional information can be found at http://www.completegenomics.com.

# # #